Queen Square Centre for Neuromuscular Diseases
- Our Services
- Our Research
- Free Access Centre Publications
- MRC Review Documents
- UK Translational Research Conference
- Studentships, Fellowships & Training
- Seminars, Conferences, Courses & Workshops
- About Us
Please click the relevant icon, to visit our Facebook group or Twitter account:
- The Centre for Neuromuscular Diseases team successfully completed their 5th bupa 10k in a row on 27th May 2013
- Launch of the John Morgan Hughes Fellowship
- A business case to develop a Neuromuscular Complex Care Centre has been approved by the UCLH Trust Executive Board
- MRC Centenary Year 2013 - info and events
- Annual Channelopathy Patient Information Day
Saturday 22nd June 2013 at Queen Square, London
- Annual Mitochondrial Patient Information Day
Saturday 6th July 2013 at Queen Square, London
- MSG Scientific Annual Meeting 2013 - Oxford
16-18 September 2013
The MRC Centre for Neuromuscular Diseases is assisting many companies currently planning or running neuromuscular trials. It is also involved in investigator-led research, and many centre collaborators are also experienced trial sites taking part in neuromuscular trials.
The list below gives brief details on each company and links to their respective websites.
Acceleron Pharma (USA)
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases.
AVI BioPharma (USA)
AVI BioPharma are focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets.
BioMarin Pharmaceutical Inc (USA)
Founded in 1997, BioMarin has developed and commercialized four products in this time. With over 700 employees and a head office in California, clinical research is conducted on an international scale with the main area of focus being rare 'orphan' genetic diseases.
First a pioneer of human genome research, Genethon now explores the new therapeutic hypotheses stemming from the extraordinary progresses of contemporary biology.
Genzyme Corporation (USA)
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with approximately 10,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion.
GlaxoSmithKline produce medicines that treat major disease areas such as asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, they are a leader in the important area of vaccines and are developing new treatments for cancer.
NOVAMEN, member of ACIES Consulting Group, specializes in collaborative research management, accompanies private and public stakeholders in European research in the strategic and operational management of their collaborative research projects, with a particular focus on European Union Framework Projects.
Since Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849, the pharmaceutical company has remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well being for people around the world.
Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular disorders.
PTC Therapeutics (USA)
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
Santhera Pharmaceuticals (Switzerland)
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of orphan neuromuscular diseases. Santhera currently has three compounds in seven clinical-stage development programs.
Shire plc is a rapidly growing global specialty biopharmaceutical company.
Shire has a global sales and marketing infrastructure with a broad portfolio of products and its own direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Belgium, Italy and Spain.
Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of partner funded drug programmes and a commercial strategy of signing multiple early-stage deals.
Founded in 1999 Trophos has 25 employees and is based in Marseille, France. Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology.